PMV Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from PMV Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 91% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.1 times its market value (net cash). Higher than 90% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-109.7×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 83% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-182.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than 91% of Healthcare companies in United States.
Cash Cushion Ratio
1.1× cashCash, after subtracting all debt, is 1.1 times its market value (net cash).
Higher than 90% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
PMV Pharmaceuticals, Inc. made a loss over the last year. PMV Pharmaceuticals, Inc. owes $0.13 for every $1 it owns. PMV Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossPMV Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.38The share price is 1.38 times PMV Pharmaceuticals, Inc.'s book value per share, lower than 71% of Healthcare companies in United States.
Market cap
$99 MThe total market value of all of PMV Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), smaller than 66% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$72 MWhat PMV Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.95Net worth divided by the number of shares. The share price of $1.30 is 1.4 times this, which is the P/B above.
Return on equity (ROE)
-70.9%PMV Pharmaceuticals, Inc. lost 70.9% of its shareholders' money over the last year, lower than 61% of Healthcare companies in United States.
Owes vs Owns
0.13×PMV Pharmaceuticals, Inc. owes $0.13 for every $1 it owns (low), lower than 82% of Healthcare companies in United States.
Dividend yield
NonePMV Pharmaceuticals, Inc. does not currently pay a dividend.
Profit growth
LossPMV Pharmaceuticals, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashPMV Pharmaceuticals, Inc. held $112 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For PMV Pharmaceuticals, Inc.: $99 M ÷ $72 M (30 Jun 2026) = 1.4.
What is PMV Pharmaceuticals, Inc.'s return on equity?
PMV Pharmaceuticals, Inc. lost 70.9% of its shareholders' money over the last year, lower than 61% of Healthcare companies in United States.
How much does PMV Pharmaceuticals, Inc. owe compared with what it owns?
PMV Pharmaceuticals, Inc. owes $0.13 for every $1 it owns (low), lower than 82% of Healthcare companies in United States.
Does PMV Pharmaceuticals, Inc. pay a dividend?
No. PMV Pharmaceuticals, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.